Pathological relationship between circulating tumor DNA and EGFR,KRAS and NRAS mutant resectable non-small cell lung cancer

WANG Lei; LIU Xian; WU Qing-hui; GAO Ke

doi:10.11659/jjssx.11E023028

您当前的位置：

首页 >

文章列表页 >

Pathological relationship between circulating tumor DNA and EGFR,KRAS and NRAS mutant resectable non-small cell lung cancer

Clinical Research | 更新时间：2025-01-21

- Pathological relationship between circulating tumor DNA and EGFR,KRAS and NRAS mutant resectable non-small cell lung cancer
- JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY Vol. 34, Issue 2, Pages: 154-158(2025)
- 作者机构：
  
  成都市第二人民医院胸心外科，四川成都 610017
- 作者简介：
- 基金信息：
- DOI：10.11659/jjssx.11E023028
  CLC： R734.1
- Published：25 February 2025，
  
  Received：07 November 2023，
- 稿件说明：
移动端阅览
WANG LEI, LIU XIAN, WU QING-HUI, et al. Pathological relationship between circulating tumor DNA and EGFR,KRAS and NRAS mutant resectable non-small cell lung cancer. [J]. Journal of regional anatomy and operative surgery, 2025, 34(2): 154-158.
DOI：

WANG LEI, LIU XIAN, WU QING-HUI, et al. Pathological relationship between circulating tumor DNA and EGFR,KRAS and NRAS mutant resectable non-small cell lung cancer. [J]. Journal of regional anatomy and operative surgery, 2025, 34(2): 154-158. DOI： 10.11659/jjssx.11E023028.

摘要

目的

探讨循环肿瘤DNA（ctDNA）与表皮生长因子受体基因（EGFR）、Kirsten大鼠肉瘤病毒癌基因（KRAS）、神经母细胞瘤RAS病毒致癌基因（NRAS）突变型可切除非小细胞肺癌（NSCLC）患者临床病理特征的关系。

方法

纳入在我院接受手术切除并且在生物库中有匹配血浆样本的36例NSCLC患者进行突变分析。使用肽核酸钳制PCR法分析血浆ctDNA和活检组织EGFR、KRAS、NRAS突变，探讨血浆ctDNA脱落与患者临床病理特征的关系。

结果

36例患者活检组织和血浆样本中EGFR、KRAS、NRAS的一致性分别为63.89%（23/36）、88.89%（32/36）、86.11%（31/36）。在突变型肿瘤中，血浆ctDNA中EGFR、KRAS、NRAS突变检测的敏感度分别为23.53%（4/17）、33.33%（2/6）、40.00%（2/5）。在腺癌患者中，血浆ctDNA脱落与较高的肿瘤分期、N分期、TNM分期、肿瘤坏死率、10HPFs核分裂象及较大的肿瘤最大直径、肿瘤体积有关（

0.05）。在肺腺癌患者亚组分析中，ctDNA脱落与较高的N分期、血管浸润率、肿瘤坏死率、10HPFs核分裂象及更大的肿瘤最大直径、肿瘤体积显著相关（

0.05）。

结论

肺腺癌ctDNA脱落与原发性肿瘤的直径、体积以及侵袭性组织学特征（如坏死和高核分裂象）有关。

Abstract

Objective

To investigate the relationship between the circulating tumor DNA （ctDNA） and the clinicopathological features of epidermal growth factor receptor gene （EGFR），Kirsten rat sarcoma viral oncogene （KRAS），and neuroblastoma RAS viral oncogene （NRAS） in patients with mutant resectable non-small cell lung cancer （NSCLC）.

Methods

Thirty-six patients with NSCLC who underwent surgical resection in our hospital and had matched plasma samples in the biobank were included for mutation analysis.The EGFR，KRAS and NRAS mutations of plasma ctDNA and biopsy tissue were analyzed by peptide nucleic acid clamp PCR to explore the relationship between plasma ctDNA shedding and clinicopathological features of patients.

Results

The consistency of EGFR，KRAS and NRAS in biopsy tissue and plasma samples of 36 pa

tients was 63.89% （23/36），88.89% （32/36） and 86.11% （31/36），respectively. In mutant tumors，the sensitivity of EGFR，KRAS and NRAS mutation detection in plasma ctDNA was 23.53% （4/17），33.33% （2/6） and 40.00% （2/5），respectively. In patients with adenocarcinoma，plasma ctDNA shedding was associated with higher tumor stage，N stage，TNM stage，tumor necrosis rate，mitotic count 10HPFs，larger maximum tumor diameter and tumor volume （

0.05）.In subgroup analysis of lung adenocarcinoma patients，ctDNA shedding was significantly associated with higher N stage，vascular invasion rate，tumor necrosis rate，and mitotic count 10HPFs，as well as larger maximum tumor diameter and tumor volume （

0.05）.

Conclusion

The shedding of ctDNA in lung adenocarcinoma is associated with primary tumor diameter，volume，and aggressive histological features （such as necrosis and high mitotic count）.

关键词

非小细胞肺癌循环肿瘤DNA基因突变肽核酸钳制PCR法

Keywords

non-small cell lung cancercirculating tumor DNAgene mutationpeptide nucleic acid clamp PCR

references

Tivey A，Church M，Rothwell D，et al.Circulating tumour DNA：looking beyond the blood［J］.Nat Rev Clin Oncol，2022，19（9）：600-612.doi：10.1038/s41571-022-00660-yhttp://dx.doi.org/10.1038/s41571-022-00660-y.

Abbosh C，Birkbak NJ，Swanton C.Early stage NSCLC：challenges to implementing ctDNA-based screening and MRD detection［J］.Nat Rev Clin Oncol，2018，15（9）：577-586.doi：10.1038/s41571-018-0058-3http://dx.doi.org/10.1038/s41571-018-0058-3.

Li N，Wang BX，Li J，et al.Perioperative circulating tumor DNA as a potential prognostic marker for operable stage Ⅰ to ⅢA non-small cell lung cancer［J］.Cancer，2022，128（4）：708-718.doi：10.1002/cncr. 33985http://dx.doi.org/10.1002/cncr.33985.

Avanzini S，Kurtz DM，Chabon JJ，et al.A mathematical model of ctDNA shedding predicts tumor detection size［J］.Sci Adv，2020，6（50）：eabc4308-eabc4316.doi：10.1126/sciadv.abc4308http://dx.doi.org/10.1126/sciadv.abc4308.

Duffy MJ.Circulating tumour DNA as a cancer biomarker［J］.Ann Clin Biochem，2019，56（1）：42-48.doi：10.1177/0004563218798401http://dx.doi.org/10.1177/0004563218798401.

Maron SB，Chase LM，Lomnicki S，et al.Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma［J］.Clin Cancer Res，2019，25（23）：7098-7112.doi：10.1158/1078-0432.CCR-19-1704http://dx.doi.org/10.1158/1078-0432.CCR-19-1704.

中华医学会，中华医学会肿瘤学分会，中华医学会杂志社.中华医学会肺癌临床诊疗指南（2018版）［J］.中华肿瘤杂志，2018，40（12）：935-964.doi：10.3760/cma.j.issn.0253-3766.2018.12.012http://dx.doi.org/10.3760/cma.j.issn.0253-3766.2018.12.012.

李兴睿，徐滔.美国癌症联合委员会第8版分化型甲状腺癌TNM分期更新解读［J］.临床外科杂志，2019，27（1）：33-35.doi：10.3969/j.issn.1005-6483.2019.01.009http://dx.doi.org/10.3969/j.issn.1005-6483.2019.01.009.

Wepy C，Nucci MR，Parra-Herran C.A typical endometriosis：comprehensive characterization of clinicopathologic，immunohistochemical，and molecular features［J］.Int J Gynecol Pathol，2024，43（1）：70-77.doi：10.1097/PGP.0000000000000952http://dx.doi.org/10.1097/PGP.0000000000000952.

Judd J，Abdel Karim N，Khan H，et al.Characterization of KRAS mutation subtypes in non-small cell lung cancer［J］.Mol Cancer Ther，2021，20（12）：2577-2584.doi：10.1158/1535-7163.MCT-21-0201http://dx.doi.org/10.1158/1535-7163.MCT-21-0201.

Loft M，To YH，Gibbs P，et al.Clinical application of circulating tumour DNA in colorectal cancer［J］.Lancet Gastroenterol Hepatol，2023，8（9）：837-852.doi：10.1016/S2468-1253（23）00146-2http://dx.doi.org/10.1016/S2468-1253（23）00146-2.

Sant M，Bernat-Peguera A，Felip E，et al.Role of ctDNA in breast cancer［J］.Cancers （Basel），2022，14（2）：310-323.doi：10.3390/cancers14020310http://dx.doi.org/10.3390/cancers14020310.

Labiano I，Huerta AE，Arrazubi V，et al.State of the art：ctDNA in upper gastrointestinal malignancies［J］.Cancers （Basel），2023，15（5）：1379-1404.doi：10.3390/cancers15051379http://dx.doi.org/10.3390/cancers15051379.

Ou SI，Hong JL，Christopoulos P，et al.Distribution and detectability of EGFR exon 20 insertion variants in NSCLC［J］.J Thorac Oncol，2023，18（6）：744-754.doi：10.1016/j.jtho.2023.01.086http://dx.doi.org/10.1016/j.jtho.2023.01.086.

Han JY，Choi JJ，Kim JY，et al.PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer［J］.BMC Cancer，2016，16（1）：627-636.doi：10.1186/s12885-016-2678-2http://dx.doi.org/10.1186/s12885-016-2678-2.

窦世华，谢鸿生，杨林.基于ctDNA的MRD检测在早期非小细胞肺癌根治术后的应用价值［J］.中国肺癌杂志，2021，24（12）：862-866.doi：10.3779/j.issn.1009-3419.2021.102.44http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.44.

杨会珍，赵幸汝，张晓菊，等.表皮生长因子受体-酪氨酸激酶抑制剂治疗后耐药的肺腺癌患者二次组织活检与外周血基因特征一致性分析［J］.中华实用诊断与治疗杂志，2021，35（3）：272-275.doi：10.13507/j.issn.1674-3474.2021.03.015http://dx.doi.org/10.13507/j.issn.1674-3474.2021.03.015.

Le NQK，Kha QH，Nguyen VH，et al.Machine learning-based radiomics signatures for EGFR and KRAS mutations prediction in non-small-cell lung cancer［J］.Int J Mol Sci，2021，22（17）：9254-9267.doi：10.3390/ijms22179254http://dx.doi.org/10.3390/ijms22179254.

Li D，Ding L，Ran W，et al.Status of 10 targeted genes of non-small cell lung cancer in eastern China：a study of 884 patients based on NGS in a single institution［J］.Thorac Cancer，2020，11（9）：2580-2589.doi：10.1111/1759-7714.13577http://dx.doi.org/10.1111/1759-7714.13577.

Li Y，Xu Z，Wang S，et al.Disease monitoring of epidermal growth factor receptor （EGFR）-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA［J］.Thorac Cancer，2022，13（15）：2201-2209.doi：10.1111/1759-7714.14545http://dx.doi.org/10.1111/1759-7714.14545.

Abbosh C，Birkbak NJ，Wilson GA，et al.Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution［J］.Nature，2017，545（7655）：446-451.doi：10.1038/nature22364http://dx.doi.org/10.1038/nature22364.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Predictive efficacy of minimal residual disease detection based on ctDNA on survival of non-small cell lung cancer after radical surgery

Relationship between the expression of serum lncRNA XIST and miR-126-3p in non-small cell lung cancer and recurrence after radical surgery

Application of single-port thoracoscopic surgery for non-small cell lung cancer in the elderly

Role and mechanism of miR-519d in brain metastasis of non-small cell lung cancer

Mechanism of circAGFG1 on biological behavior of non-small cell lung cancer

Related Author

ZHOU Wei

CHEN Zheng-yu

XIONG Jing

LI Qiang

ZHAO Qiao-dan

LIANG Dong

AI Cheng

ZENG Chao

Related Institution

First Clinical College,Chongqing Medical University/Department of General Medicine/Department of Thoracic Surgery,First Affiliated Hospital of Chongqing Medical University

Basic Medical College,Chongqing Medical University

Department of Thoracocardiac Surgery,Bishan Hospital Affiliated to Chongqing Medical University

Department of Neurology，the 74th Group Army Hospital of the People's Liberation Army of China

Department of Cardiothoracic Surgery，General Hospital of Southern Theater Command of the People's Liberation Army of China

⁰